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ABSTRACT 
 
Objectives:  There is currently a lack of data regarding antimicrobial use among public hospitals in 
South Africa (SA). This is a concern given their growing use and increasing antimicrobial resistance 
rates in SA. Consequently, the objectives of this study were to firstly determine the appropriateness of 
point prevalence survey (PPS) data collection instruments for performing antimicrobial utilisation 
studies among public sector hospitals in SA; secondly, to determine current antimicrobial utilisation in 
a public sector hospital, and thirdly evaluate the prescribing of antimicrobials with those contained 
within the national Essential Medicines List and Standard Treatment Guidelines (EML/ STGs). The 
findings will be used to guide future activities in SA. Methods: A PPS was conducted in Dr George 
Mukhari Academic Hospital. For each in-patient ward, all patients’ files were completely surveyed on 
a single day. The number of patients who were on antimicrobials served as the numerator and the 
denominator comprised the total number of patients in the ward. Results: 39 wards and 512 patient 
files were surveyed. The overall prevalence of antimicrobial use was 38.5%, highest in the ICUs. Beta 
lactamase inhibitors and antimicrobials for tuberculosis were the most prevalent antimicrobials. More 
than two thirds (83%) of antimicrobial treatment was modified following culture sensitivity test results 
when requested, and 98% of antimicrobials prescribed were contained within the current EML/ STGs. 
In 10.8% of occasions, antimicrobials appear to have been prescribed other than for treatment, i.e. no 
systemic infection. There were concerns though with the lack of IV to oral switching. Conclusion: The 
PPS method offers a standardized tool that can be used to identify targets for quality improvement. 
However, there were concerns with the time taken to conduct PPS studies, which is an issue in 
resource limited situations. This is being addressed alongside concerns with the lack of IV to oral 
switching. 
 
1. INTRODUCTION 
 
Antimicrobials play a vital role in reducing morbidity and mortality through the management of 
infection [1-3]. They reduce mortality by 10% to 75% depending on the disease area, with estimates 
suggesting life expectancy is increased by 20 years with their use [4]. However, their excessive 
utilisation has appreciably increased antimicrobial resistance rates (AMR), which is now a global 
concern [5-8]. With the diminishing effectiveness of antimicrobials, the world is facing a major 
predicament of how infections will be treated in the future. This is leading to calls to develop global 
and national action plans to reduce morbidity, mortality and costs associated with AMR, including 
increased governance [3-4, 8-12]. 
 
The World Health Organization (WHO) and others have for many years promoted the monitoring of 
antimicrobial use across sectors and raised awareness of the consequences of AMR, which includes 
the WHO Africa region [8,13-21]. These activities include the instigation of point prevalence surveys 
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(PPS) in hospitals to provide data on current utilisation and resistance patterns using a standardised 
methodology to plan future interventions [20-29]. This is particularly important in sub-Sahara Africa, 
including South Africa, with high rates of infectious diseases including HIV, malaria and tuberculosis 
(TB) [26,30-35]. In addition, in South Africa there are growing resistance to penicillins as well as non-
β-lactam antibiotics, including the macrolides, tetracycline, chloramphenicol, the fluoroquinolones and 
co-trimoxazole [36]. It has been estimated that over 50% of isolates in hospitals in South Africa are 
methicillin resistant Staphylococcus aureus (MRSA), with up to 75% of Klebsiella pneumoniae 
isolates having extended spectrum beta-lactamase (ESBL) activity, and with K. pneumoniae showing 
a higher rate of resistance than E. coli bacteraemia. There have also been outbreaks of vancomycin-
resistant Enterococci (VRE), as well as K. pneumoniae resistance against carbapenems [3,17,37,38]. 
These concerns have resulted in the development of plans in South Africa to improve antibiotic 
utilisation and reduce resistance rates across all sectors in the coming years. This includes regular 
updates on treatment guidance via mobile technologies as there have been concerns with 
inappropriate antimicrobial use against current guidelines, and the recognized need for improved 
surveillance tools [3,4,34,39-43]. 
 
In addition, a PPS conducted between April and August 2015 in a large tertiary hospital in Cape 
Town, South Africa, indicated that 31% (359/1156) of patients were receiving antibiotics and the 
majority (83%) of antibiotic prescriptions were empirical [44]. The implication of these results is that 
antibiotics were administered in public hospitals without the availability of cultures. In addition, only a 
few doctors (11%) documented the stop/review date on the prescription.  
Data on antibiotic utilisation were also collected in a number of hospitals in the Gauteng Province 
during World Antibiotic Awareness Week in 2015. However, these data were not sufficiently robust to 
make reliable and valid interpretations and recommendations, highlighting the need for assessing 
antimicrobial utilisation using valid and reliable surveillance tools such as a PPS study design to 
provide a reliable baseline for future surveys and interventions, ultimately aiming at increasing rational 
antimicrobial use.  This is particularly important as a recent study in SA using antimicrobial 
procurement as data source (one of the approaches in obtaining antimicrobial utilization data), 
showed a substantial increase in their utilisation in the public sector in recent years, which needs to 
be addressed to reduce AMR rates [11]. 
 
Overall, there is a paucity of reliable data on the use of antimicrobials among public hospitals in South 
Africa. This is a concern as the vast majority of patients in South Africa are currently treated in the 
public sector in South Africa [34]. This prompted undertaking this study to determine antimicrobial 
consumption at Dr George Mukhari Academic Hospital (DGMAH) using a PPS method, building on 
the earlier study in Cape Town [44]. Information was obtained with PPS data collection instruments 
that were initially developed in Botswana with input from the WHO, building on the European Centre 
for Disease Prevention and Control (ECDC) and Global studies [21, 22, ]. The forms were 
subsequently refined following a pilot study in Botswana before being used throughout Botswana and 
subsequently in South Africa [26,45-47]. The findings will assist with the instigation of pertinent 
programs in this hospital to improve future antimicrobial use. We also believe the study results will 
help with assessing the feasibility of using a PPS design within public hospitals in South Africa to 
identify additional targets for quality improvement programs regarding antimicrobial utilisation. This is 
particularly important given, as mentioned, the high rate of infectious diseases in South Africa as well 
as growing antimicrobial use in the public sector. 
 
2. METHODS 
2.1 Study design, setting and study period 
The study design was a PPS. Within a PPS design, all beds in a single ward are completely surveyed 
on one day to be able to correctly calculate the denominator and the numerator [. The study forms 
were based on those subsequently used for the PPS in Botswana following the pilot. As mentioned, 
they were adapted for the African setting based on input from the WHO and personnel involved in 
both the ECDC and Global PPS studies [2-22,26]. This included greater recognition of the higher 
prevalence of HIV, TB and malaria in sub-Sahara Africa than currently seen in Western countries, 
which is important for comparison purposes [20,26,30-34].   
 
Data was collected over a period of two months, from February to March 2017 at DGMAH. DGMAH 
was chosen as it is a public sector hospital and one of four teaching hospitals in the Province and 
situated in Ga-Rankuwa, Pretoria, Gauteng Province. DGMAH is a 1,650-bed hospital with 28 clinical 
departments, 20 approved ICU beds, 60 high care beds and 17 surgical theatres, providing services 
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to an estimated 1.7 million people from the surrounding area. Consequently, providing an appropriate 
site for this initial study. 
 
Data was collected on weekdays only in order not to bias the results. The principal researcher (NND) 
collected the data together with a team of trained data collectors who were pharmacist interns. Data 
collectors reviewed medical records on the survey date to determine whether patients may have been 
receiving an antimicrobial on the day of survey. If so, the information was collected on antimicrobial 
use. There was no contact with any of the ward staff including physicians or nurses, or patients, 
during the PPS to ascertain further details as necessary as one of the outputs of the survey was to 
ascertain the extent of information contained within patients’ records. 
 
For each antimicrobial, data collectors recorded the rationale for its use, i.e., the treatment of the 
infection, whether surgical or medical prophylaxis, or a non-infection-related reason. Empirical use of 
antimicrobial drugs for suspected infections was considered treatment. For antimicrobial drugs given 
to treat infections, data collectors identified the anatomical site of the infection from the patient’s 
records only if this was recorded. The data collectors also documented any antimicrobial use in the 
previous 90 days based on data contained within the patients’ records. Antimicrobials included 
antibiotics, anti-tuberculosis medicines and antifungals in line with previous PPS studies and in view 
of the high rate of TB and use of antifungals, potentially playing a role in resistance development 
[20,27,28,34,35]. 
 
2.2 Study population and sample 
As this was a PPS, no sampling was undertaken. Data was collected only once, from all the in-patient 
wards in the hospital except for day admissions such as renal dialysis patients as well as emergency 
and accidents wards. Each ward within the hospital was surveyed only once. The wards in the 
hospital were not all necessarily surveyed on the same day, but all beds in a given ward were 
completely surveyed in one day. This ensured that the denominator (number of admitted patients) 
was calculated correctly. 
 
2.3 Data entry and analysis 
The data was taken from patients’ bed charts, which are paper-based and organized in a file, 
containing all the patients’ records. The data was subsequently captured onto Microsoft ExcelTM 
spread sheets and analysed using SPSS Version 8.0 for Windows. The entered data was 
subsequently checked for accuracy and cleaned prior to analysis. This was a descriptive, explanatory 
analysis of information including epidemiologic parameters, as well as the prevalence and degree of 
consumption of antimicrobials. This includes the number of prescriptions and drug prescription 
profiles considering different ages and genders. Descriptive statistics were performed on the retrieved 
data. Categorical variables were calculated as percentages and measures of central tendency for 
continuous variables, which included the mean with standard deviation (SD), the median with inter 
quartile range (IQR) and 95% confidence intervals (CI).   
 
Antimicrobials prescribed were analysed according to the WHO’s Anatomical Therapeutic  Chemical 
(ATC) classification of medicines (ATC level 5) [48] , the dose, frequency and route of administration.  
 
2.4 Quality of prescribing 
The appropriateness of the prescribed antimicrobials was evaluated based on whether they were 
included in the national EML/STGs [49].  We did not ascertain whether the doses of antimicrobials 
prescribed, or their indication, were in line with the national EML/ STG as undertaken in other PPS 
studies [25,50,51] as the main emphasis of this study was ascertaining whether the PPS study design 
was suitable and sustainable for collecting antimicrobial data among public hospitals in a resource 
limited setting such as South Africa.  
 
However, further analysis included whether antimicrobial sensitivity analyses were requested and 
subsequently acted upon, and whether treatment was empiric or not. The later given concerns with 
the high rate of empiric prescribing in a tertiary South African hospital in 2015 [44]. In addition, 
comparing our findings with the recently published findings of the Global PPS study as well as the 5 
African countries taking part in the Global PPS [21]. Along side this, the extent of IV to oral switching 
as the earlier study in South Africa had stated only 11% of physicians had documented the 
stop/review date on the prescription [44], which should have included an assessment for changing IV 
to oral antibiotics. 
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2.5 Ethical considerations 
Data collection commenced after receiving ethical approval from the Sefako Makgatho University 
Research Ethics Committee (SMUREC/H/210/2016:PG). Permission was thereafter obtained from the 
Chief Executive Officers of DGMAH.   Patient confidentiality was maintained at all times and unique 
identification numbers were used for all patients in order to keep them anonymous. 
 
3. RESULTS 
 
A total of 512 patient files were surveyed. This included 400 adults of which 175 (43.8%) were males 
and 225 (56.3%) females. The mean age (SD) for males was 42.25 (17.29) years and the median age 
(IQR) was 43 (28.5) years. For females, the mean age (SD) was 46.10 (18.8) years and the median 
age 43 (28) years (Table 1). Most (85%) of the admitted adults were younger than 65 years, with the 
occupation of nearly two thirds (61%) of patients unknown (Table 1). In the paediatric wards, there 
were more infants and children than neonates, with a mean (SD) age of 3 years (± 3.65) and a 
median (IQR) age of 1 (4.17). 
 
Table 1: Demographics of adult patients 
 
Parameter Male Female Total 
 
Number of adults; n (%) 
 
175 (43.8) 
 
225 (56.3) 
 
400 (100) 
Age (years) 
< 65; n (%) 
≥ 65; n (%) 
Mean (± SD) 
Median (IQR) 
 
153 (38) 
22 (6) 
42.25 (17.3) 
43 (28.5) 
 
185 (46) 
40 (10) 
46.10 (18.8) 
44 (28.0) 
 
 
338 (84.5) 
62 (15.5) 
45.1(17.9) 
43 (28.3) 
Occupation; n (%) 
Employed 
Unemployed 
unknown  
 
13 (3.3) 
45 (11.3) 
117 (29.3) 
 
9 (2.3) 
89 (22.3) 
127 (31.8) 
 
22 (5.5) 
134 (33.5) 
244 (61.0) 
Transferred in; n (%) 
Yes 
No 
Unknown 
 
45 (11.3) 
118 (29.5) 
12 (3.0) 
 
25 (6.3) 
190 (47.5) 
10 (2.5) 
 
70 (17.5) 
308 (77) 
22 (5.5) 
 
3.1 Antimicrobial use prevalence 
Of the total number of 512 patients surveyed, 193 patients received at least one antimicrobial. The 
total prevalence of antimicrobial use was 38.5%. The prevalence of antimicrobial use was the highest 
in the various ICUs (Table 2).  
 
Table 2: Antimicrobial use prevalence in the wards 
 
Ward speciality Total number of 
patients 
Patients receiving 
antimicrobials (n) 
Prevalence % 
[95% CI] 
Neonatal ICU  24 17 70.8 [52.6 - 89.0] 
Paediatric ICU 9 6 66.7 [35.9 - 97.5] 
Adult ICU 28 15 53.6 [35.1 - 72.1] 
Adult medical ward 128 60 46.9 [38.3 - 55.5] 
Haematology - Oncology 
Paediatric Medical Ward 
12 5 41.7 [13.8 - 69.6] 
Adult surgical ward 194 56 28.9 [17.0 - 40.8] 
Paediatric Medical Ward  58 19 32.8 [20.7 - 44.9] 
Obstetric and Gynaecology 50 15 3.3 [-1.7 - 8.3] 
Paediatric Surgical Ward 9 0 0.0, 0.0 
Total 512 193  
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3.2 Antimicrobial drugs administered to treat infections  
Of all the antimicrobials used to treat infections in the 193 patients, 46 (15% [95% CI: 10.92-18.88]) 
antimicrobials were used to treat clinical sepsis in 28 patients, 37 (12.0 [95% CI: 8.37 -15.63]) for 
pulmonary tuberculosis (TB) in 19 patients, 32 (10.4% [95% CI: 6.99 -13.81]) for pneumonia, and 21 
(6.8% [95% CI: 3.99 - 9.61]) for bone and joint infection as well as obstetrics and gynaecological 
infections in 17 and 14 patients respectively (Table 3). Antimicrobials were also used for prophylaxis, 
with 17 antimicrobials (5.6%) having no defined infection site for their use documented in the patient 
records with no evidence of infection and in 5.2% of occasions antibiotics were prescribed other than 
for treatment (Table 3).  
 
Table 3: Infection sites for which patients received antimicrobials 
 
Infection sitea Number of antimicrobials (%) 
[95% CI]  (n = 308) 
Number of patients (%) 
[95% CI] (n = 193) 
Clinical sepsis (bloodstream)        46 (14.9%) [10.92-18.88] 28 (14.5%) [9.53 -19.47] 
Pulmonary tuberculosis 37 (12.0%) [8.37 -15.63] 19 (9.8%) [5.61 -13.99] 
Pneumonia 32 (10.4%) [6.99 -13.81] 24 (12.4%) [7.75 -17.05] 
Bone and joint infections                  21 (6.8%) [3.99 -9.61] 17 (8.8%) [4.80 -12.79] 
Obstetrics and gynaecology 21 (6.8%) [3.99- 9.61] 14 (2.1%) [15.25 -26.75] 
Soft tissue infections 19 (6.2%) [3.51 -8.89] 14 (2.1%) [0.08 - 4.12] 
Central nervous system              17 (5.5%) [2.95 -8.05] 15 (7.8%) [4.02 -11.58] 
No defined site for infection 
with no systemic inflammation 
17 (5.6 %) [3.03 -8.17] 15 (7.8) [4.02 - 11.58 
Gastrointestinal 17 (5.5%) [2.95 -8.05] 13 (6.7%) [3.17-10.23] 
Ear, nose, and throat  12 (3.9%) [1.74 - 6.06] 10 (5.2) [2.07- 8.33] 
Urinary tract 11 (3.6%) [1.52 -5.68] 10 (5.2%) [2.07 -8.33] 
Cardiovascular   11 (3.6%) [1.52 -5.68] 9 (4.7%) [1.71 -7.69] 
Febrile neutropenia  7(2.3%) [0.63 -3.97]  6 (3.1 %) [0.65 -5.55] 
Intraabdominal 7 (2.3%) [0.63-3.97] 4 (2.1%) [0.07-4.13] 
Extra pulmonary TB 4 (1.3%) [0.034 -2.57] 3 (1.6%) [-0.17 - 3.37] 
Eye infections  3 (0.9%) [-0.15- 1.95] 3 (1.6%) [-0.17-3.37] 
Bronchitis 3 (0.97%) [-0.12 -2.06] 3 (1.6%) [-0.17 -3.37] 
Asymptomatic bacteuria  2 (0.7%) [-0.25 - 1.55] 2 (1.0%) [-0.40- 2.40] 
Genitourinary for males 2 (0.6%) [0.26 – 1.46] 
   
2 (1.0%) [-0.40 -2.40] 
Laboratory confirmed 
bacteremia 
1 (0.32 %) [-0.31 -0.95] 1 (0.5%) [-0.50 -1.50] 
Antimicrobial use other than 
treatment 
16 (5.2%) [2.72 -7.68] 16 (8.3%) [4.41 -12.19] 
a Antimicrobials could be used for more than one anatomical site of infection. 
 
3.3 Antimicrobial use by ATC 
Broad spectrum penicillins were the most commonly prescribed antimicrobials (34.1%), followed by 
the cephalosporins (17.9%) and anti-tuberculosis agents (12.0%). The least used antimicrobials were 
the tetracyclines (0.3%) (Figure1). 
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Figure 1: Antimicrobial use by ATC 
 
 
3.4 Antimicrobial use in the past 90 days prior to admission  
Less than half (44.5%) of the patients (137) who were on antimicrobials in the last 90 days prior to 
admission had been prescribed antimicrobials for up to five days, while 8.8% were taking 
antimicrobials for more than 14 days (Figure 2). The remaining patients had taken antimicrobials for 
between 6 and 14 days. 
 
Figure 2: Antimicrobial use in the past 90 days (n=137) 
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3.5 Culture and sensitivity testing (CST) (n=193), compliance to national guidelines 
(EML/STGs), and IV to oral switching 
 
In 37% of patients’ files, culture and sensitivity tests (CST) results were recorded. Where these were 
recorded, the majority (83%) of antimicrobial treatment was modified following CST results when CST 
was requested and in 12 situation (8.8%) antimicrobial treatment was not modified as per CST 
results. 
 
Most of the antimicrobial agents prescribed (98%) were from the national EML/STG.  Nearly half 
(46%) of the patients were on IV medication. However, no patient when assessed had been switched 
from IV to oral even though some patients appeared to be suitable candidates based on their notes, 
e.g. they had a stable GI tract and other antibiotics had a good oral bioavailability, which could have 
been a better choice over IV medication. However, this was not investigated further as this was not 
the principal aim of this PPS study. 
 
4. Discussion 
 
The findings show that it is feasible to collect data on current antimicrobial use within public hospitals 
in South Africa using a PPS design, building on the previous study in South Africa, the Global PPS as 
well as studies conducted in Botswana, Kenya and Zimbabwe [20, 21, 25,26,52,53]. A concern 
though was the length of time taken to complete the forms. This included the need to search for 
information in the files, which was not always there. This is a particular issue in resource limited 
situations in terms of both the costs to undertake the survey if multiple researchers are needed as 
well as available time for pharmacists and others to undertake the surveys in addition to their normal 
workloads. We have subsequently developed an APP to address these concerns, with a pilot study 
suggesting that using the APP considerably shortens survey time [54]. We are currently testing this 
APP across 44 centers in South Africa, and will be reporting the findings in due course. 
 
Antimicrobial utilization was seen among 38.5% of the patients surveyed (Table 2). This is similar to 
the previous PPS study in South Africa (31%) [44] and the consolidated findings from the Global PPS 
(34.4%) [21]. However, appreciably lower that seen recently in Botswana (70.6% of admissions were 
for infectious diseases), Kenya (54.7% to 67.7%) and 50% among the African countries taking part in 
the Global PPS study [20,21,25,26,53]. The reason for this lower rate in our study is unknown, and 
envisaged to be higher given the high prevalence of infectious diseases in South Africa [30,33-35,55]. 
In addition, prior antimicrobial exposure promotes colonization and subsequent infection with 
antimicrobial-resistant pathogens. This is known to enhance AMR rates [14]. Overall, 44.5% of 
patients in our study who had been prescribed at least one antibiotic in hospital had used 
antimicrobials in the past 90 days. These concerns will also be the subject of future projects to fully 
assess the appropriateness of antimicrobial prescribing among public hospitals in South Africa. This 
builds on recent studies in both the hospital and ambulatory care sectors in South Africa as well as 
other countries [39,43,50,56].  
 
Having said this, it was unfortunate to see a low level of CSTs requested; however, encouraging to 
see a high level of modification of antimicrobial treatment following CST results when requested. This 
is not always the case as seen in other studies performed among African countries where there has 
been a low rate of antimicrobial modification [20,25,26]. However, there were concerns that 
antimicrobial treatment was not modified in a minority (17%) following the results, and there may well 
have been situations when CST could have been ordered but not recorded or available in the files at 
the time of data collection. These are also considerations for the future. In 5.6% of occasions, an 
antimicrobial was prescribed, while there was no clear indication for its use with no signs of systemic 
infection, and on 5.2% of occasions, antimicrobials were prescribed other than for treatment (Table 3). 
This is a concern that needs to be addressed to reduce inappropriate prescribing and the potential for 
increasing AMR rates. However, we are aware that among African countries in the Global PPS, on 
29.6% of occasions no reason for antimicrobial prescribing was documented in the patients’ notes 
[21]. 
  
Most antimicrobials were used to treat infection rather than prophylaxis, similar to other studies [13, 
22, 23, 26,44] as well as the Global PPS study [21], although different to a recent PPS study in Kenya 
[25]. The high burden of TB in South Africa [6, 33,34] is a possible reason for the relatively high use of 
anti-TB agents in DGMAH (Figure 1). In line with other studies performed in SA [11, 44] and across 
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Africa [21], there was a high utilization rate of penicillins versus other antimicrobials (Figure 1).  This 
may be due to restrictions on second line antibiotics such as cephalosporins and fluroquinolones. 
Antibiotic policies to optimize the use of penicillins also help preserve newer antimicrobials [23]. 
However, care is needed as the high use of penicillins poses a risk to the development of resistance 
including methicillin resistant Staphylococcus aureus (MRSA) [12,23]. The use of penicillins along with 
the appropriateness of the use of antibiotics will now be monitored closely in DGMAH. 
 
Encouragingly as well, the majority of antimicrobials prescribed (98%) were medicines that were 
available as part of the EML.  This is higher than a study conducted in South Africa in 2003 (90%) 
[57], reflecting that STGs and the EML have been promoted for a number of years alongside support 
measures to promote prescribing according to these guidelines [34, 57]. The procurement of 
medicines in public sector hospitals is highly influenced by national standard guidelines such as the 
EML/ STGs [57] resulting in the high compliance rates seen. However, as mentioned, we will be 
looking more closely at the use of antimicrobials against STGs in this and other public sector hospitals 
in SA in the future to help enhance their use as part of quality improvement programmes. This will 
also include looking more closely at the use of antibiotics to prevent surgical site infections, including 
the length of prescribing, given concerns in SA and in a number of sub-Saharan African countries 
[43,58,59]. 
 
Of concern was that no antimicrobial was switched from IV to oral in our study even if the patient had 
a stable GIT. This may be due to lack of confidence with oral antibiotics, and this will also be explored 
in future studies in view of the cost implications and potential ways to address this [60-63]. 
 
Limitations 
We are aware of a number of limitations with this study. Firstly, the accuracy of the findings depends 
on the accuracy of the documentation in the patient’s files as this was not an interventional survey 
with no patient, nurse of physician contact for clarification or additional information. The use of data 
collectors had a positive impact in accelerating the process of data collection; however, they had to be 
continuously monitored and the data collected was greatly influenced by their accuracy and level of 
commitment. Variables such as hospital or community acquired infections were also not clear cut.  
 
In addition, we are aware that the results presented on this study were obtained from one public 
hospital in the country and any generalization to all public sector hospitals in SA based on these 
results is not possible. However, this was not the primary aim of this study. Having said this, DGMAH 
is a leading public sector hospital in South Africa and the findings could potentially be used to suggest 
improvement programmes in this and other hospitals in SA. 
 
5. Conclusion 
The PPS design is appropriate for collecting data on current antimicrobial use within public sector 
hospitals in SA. Encouragingly, there was high use of antimicrobials contained with national EMLs/ 
STGs. In addition, the results showed a high use of broad spectrum penicillins and low use of 
restricted or newer antimicrobials (e. g carbapenems), which is encouraging. CST results were also 
acted on in the majority of situations. However, there is a concern with the lack of IV to oral switching, 
and that not all suitable patients have CST and not all results are acted upon. These are suggested 
quality improvement programmes for the future. 
There was also a concern about the length of time to survey each patient and enter the findings onto 
standardized forms for analysis. Further work is now ongoing developing a standardised data 
collection tool for such surveys using a web-based application to address this concern. These findings 
will be reported in the future. 
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